Skip to main content

Advertisement

SpringerLink
Log in

A case diagnosed with IgA nephropathy during a complete remission of minimal change nephrotic syndrome treated with rituximab

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

We herein report a case of IgA nephropathy in a 20-year-old male who maintained a complete remission of minimal change nephrotic syndrome (MCNS) through the administration of rituximab (RTX). He was diagnosed with nephrotic syndrome at 4 years of age. After he relapsed frequently, he was diagnosed with MCNS at 8 years of age based on the findings of a kidney biopsy. At 13 years of age, RTX therapy was initiated to maintain a complete remission after steroid treatment. MCNS recurred twice, including the time in which the interval between the RTX administrations was long. Whenever he relapsed, remission induction was achieved using steroids, and remission maintenance was achieved using RTX. Five months after the 7th RTX administration, the serum IgA level started to increase. After the 9th RTX administration, he demonstrated microhematuria despite the urinary protein level indicating complete remission. At the 10th administration, the urinary protein and the red-blood cell casts were also observed. A renal biopsy was performed 84 months after the initial administration of RTX, and the patient was diagnosed with complications of IgA nephropathy. RTX is not considered to be a useful treatment for IgA nephropathy. The reasons for this are due to the fact that IgA1 does not decrease even following the administration of RTX, because B cells residing in the mucosa may not be deleted by RTX, and IgA production may also continue due to the presence of CD20− long-lived plasma cells. Even when administering RTX, if there are findings of glomerulonephritis on urine testing, the possibility of IgA nephropathy must be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1　
Fig. 2　

Similar content being viewed by others

References

  1. Marinos CD. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4:557–67.

    Article  Google Scholar 

  2. Kazumoto I, Mayumi S, Kandai N, Rintaro M, Nao T, Koichi K, Kenichiro M, Kunihiko A, Koichi N, Yoshiyuki O, Shori T, Ryojiro T, Hiroshi K, Hidefumi N, Kenji I, Shuichi I, Yasuo O. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273–81.

    Article  Google Scholar 

  3. Jennifer CR, Mark H, Heather NR. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12:677–86.

    Article  Google Scholar 

  4. Hitoshi S, Krzysztof K, Jan N, Zina M, Andrew BH, Matthew BR, Robert JW, Francesco S, Jiri M, Ali GG, Bruce AJ. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.

    Article  Google Scholar 

  5. de la Torre I, Leandro MJ, Edwards JC, Cambridge G. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab. Clin Exp Rheumatol. 2012;30:554–60.

    PubMed  Google Scholar 

  6. Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28:1306–13.

    Article  CAS  PubMed  Google Scholar 

  7. Henrik EM, Daniela F, Claudia G, Christoph L, Karin R, Stefanie S, Eugen F, Capucine D, Hans-Peter T, Andreas R, Thomas D. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood. 2010;116:5181–90.

    Article  Google Scholar 

  8. Khalaf K, Razzaque AA. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun Rev. 2020. https://doi.org/10.1016/j.autrev.2020.102466.

    Article  Google Scholar 

  9. Chisato U, Tomohiko N, Yuji T, Yoshitaka W, Koji S, Hitohiko M, Shuichiro F. A case of a 9-year-old girl who developed IgA nephropathy after rituximab administration for steroid-dependent minimal change nephrotic syndrome. JSPRF. 2019;39:111–4 ((in Japanese)).

    Google Scholar 

  10. Ahuja TS, Funtanilla M, de Groot JJ, Velasco A, Badalamenti J, Wilson S. IgA nephropathy in psoriasis. Am J Nephrol. 1998;18:425–9.

    Article  CAS  PubMed  Google Scholar 

  11. Diwakar L, Gorrie S, Richter A, Chapman O, Dhillon P, Al-Ghanmi F, Noorani S, Krishna MT, Huissoon A. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol. 2010;63:275–7.

    Article  PubMed  Google Scholar 

  12. Nihei Y, Haniuda K, Higashiyama M, Asami S, Iwasaki H, Fukao Y, Nakayama M, Suzuki H, Kikkawa M, Kazuno S, Miura Y, Suzuki Y, Kitamura D. Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy. Sci Adv. 2023. https://doi.org/10.1126/sciadv.add6734.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Douglas DM, Julie K, Cheryl W, Adrian P, Urjana P, Elisa AP, Lesley W, Melissa AEL, Andrew JM, Kathy DM, York P, Lea N, Jeannette YL, Bruce AJ, Jan N, Ann R, Jennifer LG, Jeffrey LB. Mice overexpressing BAFF develop a commensal flora-dependent. IgA-associated nephropathy J Clim Invest. 2011;121:3991–4002.

    Google Scholar 

  14. Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z, Wollacott AM, Suzuki Y, Pereira BJG. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019;96:104–16.

    Article  CAS  PubMed  Google Scholar 

  15. Therese V, Mikael H, Iva G, Wei Z, Marie W, Christina T, Vivianne M. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8:R167.

    Article  Google Scholar 

  16. O’Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ. BCMA is essential for the survival of long-lived bone marrow plasma cells. J EXP Med. 2004;199:91–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama, 7108602, Japan

    Mana Nishikawa, Noriaki Shimada, Motoyasu Kurahashi, Kentaro Watanabe, Motoko Kanzaki, Kosuke Fukuoka & Kenichiro Asano

Authors
  1. Mana Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noriaki Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Motoyasu Kurahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kentaro Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Motoko Kanzaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kosuke Fukuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenichiro Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mana Nishikawa.

Ethics declarations

Conflict of interest

All the authors have declared no competing interest.

Informed consent

Informed consent was obtained from the patient in the present study.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nishikawa, M., Shimada, N., Kurahashi, M. et al. A case diagnosed with IgA nephropathy during a complete remission of minimal change nephrotic syndrome treated with rituximab. CEN Case Rep (2024). https://doi.org/10.1007/s13730-024-00885-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13730-024-00885-z

Keywords

Search

Navigation